Read more

July 19, 2024
2 min read
Save

4D-150 reduces annualized anti-VEGF injection rate in wet AMD at 24 weeks

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

One intravitreal injection of 4D-150 helped reduce the mean annualized anti-VEGF injection rate in patients with wet age-related macular degeneration, according to a study presented at the American Society of Retina Specialists meeting.

“The PRISM phase 2 data at 24 weeks across a broad patient population with varying severity of disease, along with long-term data collected through up to 2.5 years, confirms 4D-150’s potential to significantly reduce the treatment burden and maintain vision through a safe, single intravitreal injection,” David Kirn, MD, co-founder and CEO of 4D Molecular Therapeutics, told Healio. “This data positions 4D-150 as an emerging long-acting, potentially best-in-class genetic medicine that can preserve vision and provide long-term disease maintenance with minimal to no downsides in terms of safety.”

David Kirn, MD

Raj K. Maturi, MD, presented data from the phase 2 population extension cohort of the PRISM trial evaluating 4D-150 gene therapy in patients with wet AMD.

“It contains aflibercept as well as interfering RNA against VEGF-C, so you have four different pathways,” Maturi said.

The population extension study included 45 patients who received an intravitreal injection of aflibercept a week before receiving one of two doses of 4D-150. A second aflibercept injection was given at day 28.

Maturi said 4D-150 was found to be safe and well tolerated by patients. There were no drug-related serious adverse events in the study.

The mean reduction in annualized anti-VEGF injections was 89% in the 3 × 1010 vg/eye group and 91% in the 1 × 1010 vg/eye group; 77% of patients in the first group were injection-free at week 24 compared with 60% in the second group.

Maturi said the 3 × 1010 vg/eye group had durable improvement in best corrected visual acuity and stable central subfield thickness. All 30 patients who received 3 × 1010 vg/eye also completed prophylactic steroids, and none of them had to restart.

“Initiation of a phase 3 program is anticipated in the near future,” Maturi said.

4DMT is working with the FDA and the European Medicines Agency to finalize a phase 3 clinical trial design with the goal of trial initiation in the first quarter of 2025, according to Kirn.

“In addition, we plan to share long-term follow-up data from the severe and broad patient populations in a regular cadence going forward to continue showcasing the durable, multiyear benefits of 4D-150 from the PRISM study,” he said. “We also expect data readouts from the SPECTRA study in diabetic macular edema in Q4 this year.”